GlassScriptPhysician profile
Cheryl Carden Bazzle
NPI 1942419643
$5,845.58
in general payments reported to CMS, 2019-2025
40 companies · $798 in 2025
The $798 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $919 · 2020: $940 · 2021: $956 · 2022: $903 · 2023: $869 · 2024: $461 · 2025: $798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,019 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,019.16 |
| Education | $109.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $788.69 | 2021-2024 | Ubrelvy, Qulipta, Vraylar |
| Amgen INC. | $720.68 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $633.16 | 2019-2025 | Amyvid, Kisunla |
| Novo Nordisk INC | $451.26 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $325.61 | 2021-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $292.10 | 2019-2025 | Austedo Xr, Austedo Xr |
| Lundbeck LLC | $277.25 | 2022-2025 | Rexulti, Vyepti |
| Bayer Healthcare Pharmaceuticals INC. | $252.45 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $195.85 | 2019-2020 | |
| Allergan, INC. | $174.27 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $161.76 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $147.00 | 2023-2025 | Gemtesa |
| Glaxosmithkline, LLC. | $119.22 | 2023-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $119.15 | 2020-2024 | Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.62 | 2019-2023 | Xifaxan |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Bazzle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.